Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 25% less
These brands contain the same active ingredient (Griseofulvin [Ultra Microsize]). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Afuvin is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Tinea Capitis: 375 mg (as a single dose or in divided doses) 4 to 6 weeks.Tinea corporis: 375 mg (as a single dose or in divided doses) 2 to 4 weeksTinea cruris: 375 mg (as a single dose or in divided doses)Tinea pedis: 375 mg (as a single dose or in divided doses) 4 to 8 weeksFingernails onychomycosis: divided dose of 750 mg at least 4 monthsToenail onychomycosis: divided dose of 750 mg at least 6 monthsPediatric Use: Approximately 7.3 mg per kg of body weight per day of ultramicrosize griseofulvin is an effective dose for most pediatric patients.On this basis, the following dosage schedule is suggested: 16-27 kg: 125 mg to 187.5 mg daily. over 27 kg: 187.5 mg to 375 mg daily. Children and infants 2 years of age and younger dosage has not been established. Clinical experience with griseofulvin in children with tinea capitis indicates that a single daily dose is effective. Clinical relapse will occur if the medication is not continued until the infecting organism is eradicated.
Side Effects
Side effects reported occasionally are oral thrush, nausea, vomiting, epigastric distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion, and impairment of performance of routine activities. Proteinuria and leukopenia have been reported rarely.
Cautions & Contraindications
Warnings & Precautions
Patients on prolonged therapy with any potent medication should be under close observation. Periodic monitoring of organ system function, including renal, hepatic and hematopoietic, should be done. Since Grisin is derived from species of Penicillium, the possibility of cross sensitivity with penicillin exists; however, known penicillin-sensitive patients have been treated without difficulty. Since a photosensitivity reaction is occasionally associated with Grisin therapy, patients should be warned to avoid exposure to intense natural or artificial sunlight. Lupus erythematosus or lupus-like syndromes have been reported in patients receiving Grisin. Grisin decreases the activity of warfarin-type anticoagulants so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after Grisin therapy. Barbiturates usually depress Grisin activity and concomitant administration may require a dosage adjustment of the antifungal agent.
Contraindications
This drug is contraindicated in patients with porphyria or hepatocellular failure and in individuals with a history of hypersensitivity to griseofulvin.